



CONTACT | Media:

+31.20.550.4488 (Amsterdam), +32.2.509.1392 (Brussels)

+351.217.900.029 (Lisbon), +44.20.7379.2789 (London)

+1.212.656.2411 (New York), +33.1.49.27.11.33 (Paris)

CONTACT | Investor Relations:

+1.212.656.5700 (New York),

+33.1.49.27.58.60 (Paris)

Arseus N.V. successfully lists on Euronext 110th new listing on Euronext this year

October 5, 2007 – Today 31,195,121 ordinary shares of the healthcare company Arseus were successfully admitted to the regulated market of Euronext, both in Brussels and Amsterdam.

The IPO consisted of a total offering of 26,468,144 shares, raising a total of €302 million, including the over-allotment of 2,968,144 shares.

The placement was approximately two times oversubscribed.

On the basis of the IPO price of €10.25, the company's market capitalization now totals €320 million.

Arseus is the 110th company to be listed on Euronext this year. A total of over €1 billion has been raised through initial public offerings on Euronext markets since the beginning of the year, representing an additional market capitalization of more than €125 billion.

Arseus (www.arseus.com) is the Professional Health division of the Omega Pharma Group and the result of an integration of the various business-to-business activities in the group. Arseus provides all products and services for the growing market of health, wellness, aesthetics and ageing populations.

ICB sector of Arseus: 4537 Medical Supplies

Arseus is traded on the NSC platform under the following codes:

Euronext Amsterdam:

Stock code: RCUSA

ISIN Code: BE0003874915

Fonds Code : 605723

Euronext Brussels:

Stock Code: RCUS

ISIN Code: BE0003874915

SVM Code: 3874.91

About NYSE Euronext

NYSE Euronext, a holding company created by the combination of NYSE Group, Inc. and Euronext N.V., commenced trading on April 4, 2007. NYSE Euronext (NYSE Euronext: NYX) operates the world's largest and most liquid exchange group and offers the most diverse array of financial products and services. NYSE Euronext, which brings together six cash equities exchanges in five countries and six derivatives exchanges in six countries, is a world leader for listings, trading in cash equities, equity and interest rate derivatives, bonds and the distribution of market data. Representing a combined \$30.8 trillion/€22.8 trillion total market capitalization of listed companies and average daily trading value of approximately \$127.0 billion/€94.0 billion (as of June 29, 2007), NYSE Euronext seeks to provide the highest standards of market quality and integrity, innovative products and services to investors, issuers, and all users of its markets.

Cautionary Note Regarding Forward-Looking Statements

This press release may contain forward-looking statements, including forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning NYSE Euronext's plans, objectives, expectations and intentions and other statements that are not historical or current facts. Forward-looking statements are based on NYSE Euronext's current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause NYSE Euronext's results to differ materially from current expectations include, but are not limited to: NYSE Euronext's ability to implement its strategic initiatives, economic, political and market conditions and fluctuations, government and industry regulation, interest rate risk and U.S. and global competition, and other factors detailed in NYSE Euronext's reference document for 2006 ("document de référence") filed with the French Autorité des Marchés Financiers (Registered on June 6, 2007 under No. R.07-0089), 2006 Annual Report on Form 10-K, as amended, and other periodic reports filed with the U.S. Securities and Exchange Commission or the French Autorité des Marchés Financiers. In addition, these statements are based on a number of assumptions that are subject to change. Accordingly, actual results may be materially higher or lower than those projected. The inclusion of such projections herein should not be regarded as a representation by NYSE Euronext that the projections will prove to be correct. This press release speaks only as of this date. NYSE Euronext disclaims any duty to update the information herein.